Q-omics provides the consensus-scored PAX7 profile across patient tissues and cancer cell-line models. PAX7 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PAX7 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, PAX7 protein abundance shows 15,085 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, LUAD, and LSCC as cancer lineages where PAX7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAX7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAX7 survival associations across molecular data types. PAX7 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAX7 RNA expression–survival associations across cancer types. High PAX7 expression shows unfavorable associations in BRCA, THCA, LUSC, KIRP, ESCA and SCLC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for PAX7 RNA expression.
This table summarizes PAX7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 2. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PAX7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAX7 shows lower tumor expression in THCA and higher tumor expression in LUAD, BRCA, LUSC and STAD. The LUAD box plot shows higher PAX7 RNA expression in tumor versus normal tissue (log2 FC = +0.960, t-test p < 0.001).
This table shows molecular features associated with PAX7 in patient tissues and cancer cell lines. In patient samples, PAX7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PAX7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
